Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPA-FFA in Familial Adenomatous Polyposis
NCT03806426Phase 3Active, not recruiting
- Sponsor
- SLA Pharma
- Start
- Dec 2018
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eicosapentaenoic acid in familial adenomatous polyposis (FAP), sponsored by SLA Pharma. Started Dec 2018; status: active, not recruiting.
02
Drugs
eicosapentaenoic acid
03
Conditions
familial adenomatous polyposis (FAP)
Beyond the preview
Go deeper on NCT03806426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03806426.